Tesamorelin / IpamorelinBlend
Tesamorelin + Ipamorelin GH-support blend.
- Status
- Research / not approved
- Developer
- Compounded research-peptide blend; vendor-specific
- Receptors / target
- Not a single target — combines tesamorelin (stabilized GHRH analog) and ipamorelin (ghrelin / GHS-R1a agonist) to stimulate pituitary GH release through two complementary pathways
- FDA-approved?
- NO
- Prescription available?
- NO
- Studied for
- growth-hormone / IGF-1 secretionvisceral fat / body compositionrecoveryGH-secretagogue pharmacology
Overview
Tesamorelin / Ipamorelin is a compounded growth-hormone secretagogue blend pairing a stabilized GHRH analog (tesamorelin) with a selective ghrelin-receptor agonist (ipamorelin). Note that tesamorelin alone is an FDA-approved drug (Egrifta, for HIV-associated lipodystrophy), but the combination with ipamorelin is not approved and has no clinical trials — it is sold research-use-only for GH/body-composition research.
Mechanism
Tesamorelin stimulates pituitary GHRH receptors to drive pulsatile growth-hormone release and downstream IGF-1; ipamorelin activates the growth-hormone secretagogue receptor (GHS-R1a, the ghrelin receptor). Because the two act through different receptors, co-stimulation is proposed to be additive on GH release. This two-pathway rationale is mechanistically reasonable, but the specific combination has not been characterized in controlled studies.
Clinical evidence
There are no human trials of the Tesamorelin/Ipamorelin blend; evidence is per component. Tesamorelin has robust phase 3 RCT evidence — but specifically for reducing visceral abdominal fat in HIV-associated lipodystrophy, its approved use — not for general body-composition or anti-aging goals. Ipamorelin reached a phase 2 trial that was well tolerated but missed its primary endpoint. No controlled human evidence supports the combination for the uses it is marketed for.
Safety profile
The combined-injection safety has not been studied. As growth-hormone secretagogues, the combination can raise GH/IGF-1 and may cause glucose intolerance, fluid retention and arthralgia (effects seen with tesamorelin), plus injection-site reactions. GHRH analogs and GH secretagogues are WADA-prohibited (S2), so this blend is banned in sport. The combination is not FDA-approved (tesamorelin's approval does not extend to it), and long-term safety of the blend is unestablished. Research-use only; nothing here is therapeutic or dosing guidance.
- Per dose (acute)
Stimulates GH release; IGF-1 rises over days. WADA-prohibited.
- Weeks
Tesamorelin alone reduces visceral fat over ~26 weeks in its approved use, but there are no trials of this combination for general body-composition goals; anecdotal.
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Injection-site reactions
- Arthralgia, fluid retention / edema
- Hyperglycemia / impaired glucose tolerance
- Unstudied combined-injection safety
If severe or unexpected symptoms occur, contact a qualified medical professional. PEPTIDES·INDEX does not provide medical advice.
- No human safety data exist for the blend; combined-injection safety is unstudied and research-use only.
- As GH secretagogues, the combination raises GH/IGF-1 and may cause glucose intolerance, fluid retention and arthralgia (effects seen with tesamorelin) — a concern in diabetes or insulin resistance.
- Elevated GH/IGF-1 raises a theoretical concern in the setting of active or prior malignancy.
- No documented human drug interactionsNo interaction studies of the combination; uncharacterized in humans (research use only)
- Insulin and other glucose-lowering medicationsGrounded caution — GH secretagogues can raise blood glucose and reduce insulin sensitivity, theoretically opposing glycemic control
Compare
- vs CJC-1295 / Ipamorelin
Sibling GH-secretagogue blend that uses CJC-1295 instead of tesamorelin as the GHRH analog.
- vs Tesamorelin
The single tesamorelin component — FDA-approved on its own for HIV-associated lipodystrophy.
- vs Ipamorelin
The single ghrelin-receptor agonist component of this blend.
FAQ
Is the Tesamorelin/Ipamorelin blend studied in clinical trials?
No. There are no human trials of the combination. Tesamorelin has robust phase 3 RCT evidence, but only for reducing visceral fat in HIV-associated lipodystrophy — not for general body-composition goals; ipamorelin reached a phase 2 trial that missed its primary endpoint. Combined benefit is unproven.
Is tesamorelin FDA-approved?
Tesamorelin alone is FDA-approved as Egrifta for HIV-associated lipodystrophy. However, the combination with ipamorelin is not approved and is sold research-use only.
Is it banned in sport?
Yes. GHRH analogs and GH secretagogues are WADA-prohibited (class S2), so this blend is banned in sport at all times.
Why combine tesamorelin with ipamorelin?
Tesamorelin acts on the GHRH receptor and ipamorelin on the ghrelin/GHS-R1a receptor, so co-stimulation through two different pathways is proposed to be additive on growth-hormone release. The rationale is mechanistically reasonable, but the specific combination has not been characterized in controlled studies — and tesamorelin's FDA approval does not extend to the blend.
How does this differ from the CJC-1295/Ipamorelin blend?
Both pair ipamorelin with a GHRH analog; the difference is the GHRH component. This blend uses tesamorelin — a stabilized GHRH analog with phase 3 RCT data and standalone FDA approval — whereas the sibling uses CJC-1295. Both blends are unstudied as combinations and both are WADA-prohibited (S2).
What are the main safety considerations?
As GH secretagogues, the combination can raise GH/IGF-1 and may cause glucose intolerance, fluid retention/edema and arthralgia (effects seen with tesamorelin in its trials), plus injection-site reactions. Combined-injection safety is unstudied, the blend is not FDA-approved, and elevated GH/IGF-1 is a theoretical concern with diabetes/insulin resistance or active or prior malignancy. Research use only — not therapeutic or dosing guidance.
Similar compounds
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.